Fieldview Capital Management LLC Invests $3.32 Million in Globus Medical, Inc. $GMED

Fieldview Capital Management LLC acquired a new position in shares of Globus Medical, Inc. (NYSE:GMED) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 37,976 shares of the medical device company’s stock, valued at approximately $3,316,000.

Several other large investors have also modified their holdings of the stock. Horizon Investment Services LLC bought a new stake in shares of Globus Medical during the 4th quarter worth $1,538,000. Kennedy Capital Management LLC raised its holdings in shares of Globus Medical by 0.3% during the fourth quarter. Kennedy Capital Management LLC now owns 492,641 shares of the medical device company’s stock worth $43,012,000 after acquiring an additional 1,692 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in shares of Globus Medical during the fourth quarter worth $1,607,000. Kestra Advisory Services LLC raised its holdings in Globus Medical by 37.7% during the fourth quarter. Kestra Advisory Services LLC now owns 8,575 shares of the medical device company’s stock valued at $749,000 after buying an additional 2,349 shares in the last quarter. Finally, Johnson Investment Counsel Inc. bought a new position in Globus Medical during the fourth quarter valued at about $214,000. 95.16% of the stock is owned by institutional investors.

Globus Medical Trading Down 0.1%

Shares of NYSE GMED opened at $80.44 on Friday. The firm has a market cap of $10.92 billion, a PE ratio of 18.71, a PEG ratio of 1.66 and a beta of 0.95. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $101.40. The company has a fifty day moving average price of $85.77 and a 200 day moving average price of $88.10.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. During the same period in the prior year, the business earned $0.68 EPS. The company’s revenue for the quarter was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Equities research analysts forecast that Globus Medical, Inc. will post 4.74 EPS for the current year.

Analyst Upgrades and Downgrades

GMED has been the topic of a number of recent analyst reports. Wall Street Zen lowered Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Truist Financial set a $115.00 target price on Globus Medical in a research report on Wednesday, February 25th. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Wells Fargo & Company dropped their price target on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $106.36.

Insider Activity at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares in the company, valued at $41,201,733. This represents a 4.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 18.38% of the stock is currently owned by corporate insiders.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.